BCL2 and central nervous system cancer: Similar with the results of glioma cells, shikonin or topotecan significantly reduced the expression of Bcl-2 as well as promoted the activation of caspase-9 and caspase-3 in GSCs-U251 and GSCs-U87 cells respectively, compared to the control groups (P<0.01).